ClinicalTrials.gg
TerminatedNCT02213133STARRSUpdated Jan 26, 2023Results posted

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

A Phase 2 interventional study of Selinexor (KPT-330) in Squamous Cell Carcinoma, sponsored by Karyopharm Therapeutics Inc. Terminated at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to enrollment challenges and availability of other options for lung cancer patients. The termination is not a consequence of any safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.

Enrollment
120th of 280
45 · median 37
Started
2014
with 16 others
Phase 2
106 of 330
23 open now
Registered
139th of 330
by date

Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 120th largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 106 in phase 2, and was the 139th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Carcinoma, Squamous Cell with a site in United States, or all of them as a file.
02

Study summary

Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.

Read the detailed description

This is a multicenter, open-label, single-arm Phase 2 study of the SINE selinexor given orally to patients diagnosed with advanced SCC of the head and neck, lung, or esophagus who have experienced relapse and/or metastasis following multiple prior chemotherapy treatments (\<2 lines of therapy).

Patients will receive fixed doses of selinexor tablets twice weekly in 28-day cycles. Patients may continue from one cycle to the next without interruption as along as all criteria are met and no reason for discontinuation occurs.

03

Conditions studied

  • Squamous Cell Carcinoma

Keywords

  • Squamous
  • SCC
  • Carcinoma
  • KPT-330
  • SINE
  • Selinexor
  • Karyopharm
  • Karyopharm Therapeutics
  • Lung
  • Head
  • Neck
  • Esophageal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • confirmed SCC of the head and neck, lung, or esophagus
  • 1 to 2 prior therapies
  • at screening and documented progression within the past 6 weeks

Exclusion criteria

Exclusion Criteria:

  • patients requiring total parenteral nutrition
  • unstable cardiovascular function
  • substantially impaired gastrointestinal function
  • Symptomatic
  • another within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort 1: Head and Neck-SCC

    Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than \[\<\] 100\*10\^9 per litre \[/L\]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.

    Drug: Selinexor (KPT-330)

  • Experimental
    Cohort 2: Lungs-SCC

    Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.

    Drug: Selinexor (KPT-330)

  • Experimental
    Cohort 3: Esophagus-SCC

    Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets \<100\*10\^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.

    Drug: Selinexor (KPT-330)

Interventions

  • Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.

    Also known as: KPT-330

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    DCR was defined as the best overall response of complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participant response was evaluated by physical examinations and computed tomography (CT)/Magnetic Resonance Imaging (MRI) (or optional positron emission tomography \[PET\]/CT) and assessed by RECIST 1.1 criteria.

    Time frame: up to 14.6 months

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any unfavorable sign and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of the study drug, whether or not related to study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose (including after informed consent was signed and prior to dosing) that resulted in death, was life-threatening (participant was at immediate risk of death from event), required in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect, and important medical events. A TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after first dose of treatment through 30 days following last dose of study treatment, or any event considered drug-related by investigator through end of study.

    Time frame: From the first administration of study drug up to 30 days follow-up (up to 14.6 months)

  2. Number of Participants With Treatment-emergent Adverse Events by Severity: Clinical Terminology Categories for Adverse Events (CTCAE) Grading Scale

    AE:Any unfavorable sign and unintended sign,symptom, or disease temporarily associated with use of study drug, whether or not related to it. SAE:Any untoward medical occurrence that occurs at any dose (after informed consent was signed, prior dosing) that resulted in death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and important medical events. TEAE:Any AE with onset or worsening of existing condition on or after first dose through 30 days following last dose of study drug, or any event considered drug-related by investigator through end of study. Severity(Grades 1 to 5) of each AE was categorized as either mild=1(transient,does not interfere with daily activities), moderate=2(low level of inconvenience or concern,interfere with daily activities), severe=3(interrupt usual daily activities), life threatening=4 or fatal=5, higher grade reported worst outcome.

    Time frame: From the first administration of study drug up to 30 days follow-up (up to 14.6 months)

07

Results

Posted Dec 7, 2020
Limitations and caveats
The study was terminated due to enrollment challenges and availability of other options for lung cancer participants. The termination was not a consequence of any safety concern.

Participant flow

The study was conducted at 14 sites in United States and 1 site in Canada between 22 September 2014 and 10 December 2015.

Participant flow — Overall Study
MilestoneCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCC
Started3753
Treated3341
Completed000
Not completed3753
Withdrew: Participant discontinued study therapy200
Withdrew: Participant withdrew informed consent212
Withdrew: Disease progression1120
Withdrew: Adverse event (ae)100
Withdrew: Death1621
Withdrew: Other500

Outcome measures

PrimaryPercentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

DCR was defined as the best overall response of complete response (CR), partial response (PR), or stable disease (SD). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participant response was evaluated by physical examinations and computed tomography (CT)/Magnetic Resonance Imaging (MRI) (or optional positron emission tomography \[PET\]/CT) and assessed by RECIST 1.1 criteria.

Time frame:
up to 14.6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
percentage of participantsCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCC
Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.121.2 (10.7 to 37.8)0.0 (0.0 to 49.0)0.0 (0.0 to 79.3)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any unfavorable sign and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of the study drug, whether or not related to study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose (including after informed consent was signed and prior to dosing) that resulted in death, was life-threatening (participant was at immediate risk of death from event), required in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect, and important medical events. A TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after first dose of treatment through 30 days following last dose of study treatment, or any event considered drug-related by investigator through end of study.

Time frame:
From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCC
Participants with TEAEs3753
Participants with SAEs1823
SecondaryNumber of Participants With Treatment-emergent Adverse Events by Severity: Clinical Terminology Categories for Adverse Events (CTCAE) Grading Scale

AE:Any unfavorable sign and unintended sign,symptom, or disease temporarily associated with use of study drug, whether or not related to it. SAE:Any untoward medical occurrence that occurs at any dose (after informed consent was signed, prior dosing) that resulted in death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and important medical events. TEAE:Any AE with onset or worsening of existing condition on or after first dose through 30 days following last dose of study drug, or any event considered drug-related by investigator through end of study. Severity(Grades 1 to 5) of each AE was categorized as either mild=1(transient,does not interfere with daily activities), moderate=2(low level of inconvenience or concern,interfere with daily activities), severe=3(interrupt usual daily activities), life threatening=4 or fatal=5, higher grade reported worst outcome.

Time frame:
From the first administration of study drug up to 30 days follow-up (up to 14.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events by Severity: Clinical Terminology Categories for Adverse Events (CTCAE) Grading Scale
ParticipantsCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCC
Mild (Grade 1)300
Moderate (Grade 2)910
Severe (Grade 3)2143
Life Threatening (Grade 4)300
Fatal (Grade 5)100

Adverse events

Collected over From the first administration of study drug up to 30 days after participant's last visit (up to 14.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Head and Neck-SCC16/37 (43.2%)18/37 (48.6%)35/37 (94.6%)
Cohort 2: Lungs-SCC2/5 (40%)2/5 (40%)5/5 (100%)
Esophagus-SCC1/3 (33.3%)3/3 (100%)3/3 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCEsophagus-SCC
TracheitisInfections and infestations0/370/52/3
DyspnoeaRespiratory, thoracic and mediastinal disorders1/370/51/3
Platelet Count DecreasedInvestigations0/370/51/3
PneumoniaInfections and infestations5/371/50/3
DeliriumPsychiatric disorders1/371/50/3
Lung InfectionInfections and infestations2/370/50/3
Mouth HaemorrhageGastrointestinal disorders2/370/50/3
Arthritis BacterialInfections and infestations1/370/50/3
Skin InfectionInfections and infestations1/370/50/3
Streptococcal BacteraemiaInfections and infestations1/370/50/3
Most frequent other events
Showing 10 of 61
Most frequent other events
EventCohort 1: Head and Neck-SCCCohort 2: Lungs-SCCEsophagus-SCC
NauseaGastrointestinal disorders25/374/50/3
FatigueGeneral disorders21/374/51/3
PyrexiaGeneral disorders3/370/52/3
AnaemiaBlood and lymphatic system disorders9/371/52/3
HyponatraemiaMetabolism and nutrition disorders15/371/51/3
VomitingGastrointestinal disorders13/372/50/3
DiarrhoeaGastrointestinal disorders5/372/51/3
Decreased AppetiteMetabolism and nutrition disorders12/372/51/3
Vision BlurredEye disorders6/372/50/3
ConstipationGastrointestinal disorders10/371/51/3

Baseline characteristics

Modified intent-to-treat population (mITT) population included all participants who had received at least one dose of study drug and had at least one post baseline efficacy assessment were included if discontinuation was due to disease progression, study drug related toxicity, or death.

Age, Continuous
Age, Continuous(years)Cohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCCTotal
Mean58.5 ± 10.0566.3 ± 6.3451.0 ± NA59.1 ± 9.91
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCCTotal
Female3104
Male303134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Head and Neck-SCCCohort 2: Lungs-SCCCohort 3: Esophagus-SCCTotal
Race — American Indian or Alaska Native0000
Race — Asian1001
Race — Native Hawaiian or Other Pacific Islander0000
Race — Black or African American0000
Race — White304135
Race — Other-unspecified1001
Race — Unknown or Not Reported1001
08

Study locations

18 sites
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Northwestern University
    Evanston, Illinois 60208, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Dana-Farber Cancer Institute / Harvard University
    Boston, Massachusetts 02215, United States
  • Metrowest Medical Center
    Framingham, Massachusetts 01702, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine / Washington University in St. Louis
    Saint Louis, Missouri 63130, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029-6574, United States
  • Herbert Irving Comprehensive Cancer Center / Columbia University
    New York, New York 10032, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Sarah Cannon Research Institute - Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt-Ingram Cancer Center / Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Mary Crowley Cancer Research Center / Texas Oncology
    Dallas, Texas 75201, United States
  • University of Washington
    Seattle, Washington 63110, United States
  • Princess Margaret Hospital
    Toronto, Ontario, Canada
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Dec 2015, 14 months.

Results were first posted in Dec 2020, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2014
First posted
Aug 11, 2014
StartActual
Sep 22, 2014
Primary completionActual
Dec 10, 2015
CompletionActual
Dec 10, 2015
Results first posted
Dec 7, 2020
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02213133
Responsible party
Sponsor
First posted
Aug 11, 2014
Start date
Sep 22, 2014
Primary completion
Dec 10, 2015
Completion
Dec 10, 2015
Results posted
Dec 7, 2020
Last update
Jan 26, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion